Search - tctmd.com

Displaying 441 - 460 of 739

Sort: Relevancy | Date

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

News Conference News HRS 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

May 17, 2019

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

TCTMD’s Top 10 Most Popular Stories for April 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2019

May 01, 2019

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

No Need for Niacin? Meta-analysis Argues the End Is Nigh

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

Disparities Seen in Uptake of DOACs for VTE

News Daily News

Disparities Seen in Uptake of DOACs for VTE

April 05, 2019

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

April 03, 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

News Conference News EHRA 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

March 17, 2019

Signal of Aortic Stenosis Risk With Celecoxib

News Daily News

Signal of Aortic Stenosis Risk With Celecoxib

Michael O'Riordan

March 05, 2019

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

News Daily News

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Michael O'Riordan

February 26, 2019

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

News Daily News

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

February 25, 2019

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

News Daily News

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

February 22, 2019

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

News Daily News

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

February 15, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.